Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H32Cl2N2O4 |
| Molecular Weight | 459.406 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCN(CCCCC)C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1
InChI
InChIKey=IEKOTSCYBBDIJC-IBGZPJMESA-N
InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)/t19-/m0/s1
| Molecular Formula | C22H32Cl2N2O4 |
| Molecular Weight | 459.406 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Lorglumide (CR1409) is the first nonpeptidic, selective and potent inhibitor of the cholecystokinin-A and cholecystokinin-B receptors. Lorglumide prevented dose-dependently the emptying of the gallbladder in both experimental models; proglumide exhibited a comparable activity at much higher doses. Lorglumide was associated with significantly inhibited cell growth of human pancreatic cancer cell line Mia PaCa-2 in vitro. Lorglumide also induced G0/G1 cell cycle arrest and apoptosis. The change of invasion ability appeared to be mediated by MMP-2 expression, which was upregulated by CCK-8S and downregulated by lorglumide. Lorglumide had been in preclinical phase for the treatment of biliary dyskinesia, pancreatitis and cancer. However, this development was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. | 1990 Sep |
|
| Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene. | 1996 Aug |
|
| Gut vagal afferents are necessary for the eating-suppressive effect of intraperitoneally administered ginsenoside Rb1 in rats. | 2015 Dec 1 |
|
| Postsynaptic Depolarization Enhances GABA Drive to Dorsomedial Hypothalamic Neurons through Somatodendritic Cholecystokinin Release. | 2015 Sep 23 |
|
| Peripheral apelin-13 administration inhibits gastrointestinal motor functions in rats: The role of cholecystokinin through CCK(1) receptor-mediated pathway. | 2017 Jun |
|
| UCN3 suppresses food intake in coordination with CCK and the CCK2R in Siberian sturgeon (Acipenser baerii). | 2019 Aug |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:30:23 UTC 2023
by
admin
on
Sat Dec 16 10:30:23 UTC 2023
|
| Record UNII |
357WD8CT34
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6604124
Created by
admin on Sat Dec 16 10:30:23 UTC 2023 , Edited by admin on Sat Dec 16 10:30:23 UTC 2023
|
PRIMARY | |||
|
118919-28-1
Created by
admin on Sat Dec 16 10:30:23 UTC 2023 , Edited by admin on Sat Dec 16 10:30:23 UTC 2023
|
PRIMARY | |||
|
357WD8CT34
Created by
admin on Sat Dec 16 10:30:23 UTC 2023 , Edited by admin on Sat Dec 16 10:30:23 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
